Recurrent primary central nervous system lymphoma complicated by lymphomatous meningitis

Oncology Reports

Volumn 5, Issue 2, 1998, Pages 521-525

  Chamberlain, Marc C ^a   Kormanik, Patty ^a   Glantz, Michael ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Lymphomatous meningitis; Primary central nervous system lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; METHOTREXATE; THIOTEPA;

ADULT; AGED; ARTICLE; ASEPTIC MENINGITIS; BONE MARROW SUPPRESSION; BRAIN LYMPHOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; LEUKOENCEPHALOPATHY; MALE; MENINGITIS; PARENCHYMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR RECURRENCE;

EID: 0031952131     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.5.2.521     Document Type: Article

References (23)

1. Chamberlain MC and Levin VA: Primary central nervous system lymphoma: A role for adjuvant chemotherapy. J Neuro-Oncol 14: 271-275, 1992.
2. Cher L, Glass J, Harsh GR and Hochberg FH: Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: Preliminary results. Neurology 46: 1757-1759, 1996.
3. Glass J, Gruber ML, Cher L and Hochberg FH: Pre-irradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 81: 188-195, 1994.
4. Neuwelt EA, Goldman DL, Dahlborg SA, et al: Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: Prolonged survival and preservation of cognitive function. J Clin Oncol 9: 1580-1590, 1991.
5. Tomlinson FH, Kurtin PJ, Suman VJ, et al: Primary intracerebral malignant lymphoma: A clinicopathological study of 89 patients. J Neurosurg 82: 558-566, 1995.
6. Velasquez WS: Primary central nervous system lymphoma. J Neuro-Oncol 20: 177-185, 1994.
7. Chamberlain MC and Levin VA: Adjuvant chemotherapy for primary lymphoma of the central nervous system. Arch Neurol 47: 1113-1116, 1990.
8. DC Angelis LM. Yahalom J, Thaler HT and Kher U: Combined modality therapy for primary CNS lymphoma. J Clin Oncol 10: 635-643, 1992.
9. Hochberg FH, Loeffler JS and Prados M: The therapy of primary brain lymphoma. J Neuro-Oncol 10: 191-201, 1991.
10. Freilich RJ, Delattre JY, Monjour A and De Angelis M: Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 46: 435-439, 1996.
11. MacDonald DR: New therapies of primary CNS lymphomas and oligodendrogliomas. J Neuro-Oncol 24: 97-101, 1995.
12. Chamberlain MC and Dirr L: Involved field radiotherapy and intra-Ommaya methotrexate/ara-C in patients with AIDS-related lymphomatous meningitis. J Clin Oncol 11: 1978-1993, 1993.
13. Lachance DH, O'Neill BP, MacDonald DR, et al: Primary leptomeningeal lymphoma: Report of 9 cases, diagnosis with immunocytochemical analysis, and review of the literature. Neurology 41: 95-100, 1991.
14. Balmaceda C, Gaynor JJ, Sun M, et al: Leptomeningeal tumor in primary central nervous system lymphoma: Recognition, significance and implications. Ann Neurol 38: 202-209, 1995.
15. Chamberlain MC: New approaches to and current treatments of leptomeningeal metastases. Curr Opin Neurol 7: 492-500, 1994.
16. Grossman S and Moynihan T: Neurologic complications of systemic cancer, neoplastic meningitis. Neurol Clin 9: 843-856, 1991.
17. Chamberlain MC and Corey-Bloom J: Leptomeningeal metastasis: Indium-DTPA CSF flow studies. Neurology 41: 1765-1769, 1991.
18. Chamberlain MC: Comparative spine imaging in leptomeningeal metastases. J Neuro-Oncol 23: 233-238, 1995.
19. Chamberlain MC, Sandy A and Press GA: Leptomeningeal metastasis: A comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 40: 435-438, 1990.
20. 111Indium-DTPA CSF flow studies. Neurology 46: 1674-1677, 1996.
21. Shapiro WR, Young DF and Mehta BM: Methotrexate: Distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 293: 161-166, 1975.
22. Armitage JO: Treatment of non-Hodgkin's lymphoma. Drug Therapy 328: 1023-1030, 1993.
23. MacDonald DR, Cascino TL, Schald SC et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280, 1990.